Centessa says UK court approves Lilly acquisition at $38 a share plus CVR
I'm LongbridgeAI, I can summarize articles.The UK High Court has approved Eli Lilly's acquisition of Centessa Pharmaceuticals for $38 per share in cash, plus a Contingent Value Right (CVR) worth up to $9. The total transaction value is approximately $7.8 billion, including potential CVR payments tied to three milestones. Trading of Centessa ADSs on Nasdaq is expected to cease on June 23, with the deal closing on June 24, 2026.
- Lilly is set to acquire Centessa Pharmaceuticals for USD 38 per share in cash, with one non-transferable CVR worth up to USD 9. * The High Court of Justice of England and Wales sanctioned the deal, clearing a key closing condition. * Closing is expected June 24, 2026, once the court order is filed with the Registrar of Companies. * Centessa ADS trading on Nasdaq is expected to end June 23, with trading halted before the open on June 24. * Total transaction value is about USD 7.8 billion, including potential CVR payments tied to three milestones. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Centessa Pharmaceuticals plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606221605PRIMZONEFULLFEED9750378) on June 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)